stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Return on assets
Grifols, S.A.'s return on assets over the twelve months to 30 September 2026 was 2.28%, up 0.3 percentage points from fiscal 2025 (2.00%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 6.36% (fiscal 2017); the current reading is higher than 67% of that period. That is in line with the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 2.00% | 1.27 |
| FY2024 | 0.73% | 0.45 |
| FY2023 | 0.28% | (0.69) |
| FY2022 | 0.97% | 0.97 |
| FY2022 | 0.00% | (1.11) |
| FY2021 | 1.11% | 1.11 |
| FY2021 | 0.00% | (4.05) |
| FY2020 | 4.05% | 4.05 |
| FY2020 | 0.00% | (4.36) |
| FY2019 | 4.36% | 4.36 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 20.5% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi compare | 3.24% |
| GRFS Grifols, S.A. | 2.28% |
| OGN Organon & Co. compare | 1.58% |
| BIIB Biogen Inc. compare | 1.13% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| AMRN Amarin Corporation PLC compare | −2.96% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement